@article {Wallace:April 2005:1568-0266:215,
	author = "Wallace, Eli M.",
	author = "Lyssikatos, Joseph P.",
	author = "Yeh, Tammie",
	author = "Winkler, James D.",
	author = "Koch, Kevin",
	title = "Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy",
	journal = "Current Topics in Medicinal Chemistry",
	volume = "5",
	year = "April 2005",
	abstract = "This paper reviews recent progress in the design and evaluation of MEK inhibitors as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in 50% of colon, 90% of pancreatic and 30% of lung cancers. Recently, B-Raf mutations have been identified in more than 60% of malignant melanomas and from 40-70% of papillary thyroid cancers. MEK, a dual specificity kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. Representative examples of both ATP competitive and non-competitive inhibitors as well as natural product based inhibitors will be discussed.",
	pages = "215-229(15)",
	url = "http://www.ingentaconnect.com/content/ben/ctmc/2005/00000005/00000002/art00009"
	doi = "doi:10.2174/1568026053507723"
}